Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications
May 18, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of...
Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA
May 15, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
OTL-200 Biologics License Application (BLA) submission completion anticipated in mid-2023 Libmeldy revenue and commercial patients treated expected to grow year-over-year in 2023 New clinical data...
Orchard Therapeutics Announces New Clinical and Pre-clinical Data at ASGCT 2023
May 03, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Six presentations showcase the differentiated profile and broad applicability of the company’s HSC gene therapy platform Oral presentations in MPS-IH and MPS-IIIA and the progranulin form of...
Orchard Therapeutics to Present at Guggenheim Genomic Medicines and Rare Disease Day
March 30, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 30, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will make a virtual presentation at the...
Orchard Therapeutics Completes ADS Ratio Change
March 10, 2023 10:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its...
Orchard Therapeutics Provides Business Update and Reports 2022 Financial Results
March 06, 2023 06:05 ET
|
Orchard Therapeutics (Europe) Limited
OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) Strategic financing from leading healthcare...
Orchard Therapeutics Announces Strategic Financing Totalling up to $188 Million
March 06, 2023 06:00 ET
|
Orchard Therapeutics (Europe) Limited
Proceeds to accelerate commercialization of Libmeldy and advance the company’s HSC gene therapy R&D portfolio Initial closing of $34 million to support execution and extend cash runway into 2025...
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2023
March 03, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that members of the management team will present at the...
Orchard Therapeutics Announces Agreement Enabling Reimbursed Access to Libmeldy for All Eligible MLD Patients in Sweden
February 27, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
BOSTON and LONDON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced it has reached an agreement with the New Therapies (NT)...
Orchard Therapeutics Announces Presentation of Updated Integrated Analysis of OTL-200 in MLD and Reports Progress with Newborn Screening Efforts at the 19th Annual WORLDSymposium™
February 24, 2023 07:00 ET
|
Orchard Therapeutics (Europe) Limited
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 11 years of follow-up (median 6.15 years) Composite...